Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide

Leuk Lymphoma. 2017 Oct;58(10):2511-2513. doi: 10.1080/10428194.2017.1295146. Epub 2017 Feb 28.

Authors

Satoko Oka¹, Kazuo Ono², Masaharu Nohgawa¹

Affiliations

¹ a Division of Hematology , Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.
² b Division of Pathology , Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.

PMID: 28278708
DOI: 10.1080/10428194.2017.1295146

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Biomarkers, Tumor / genetics
Cell Transformation, Neoplastic / chemically induced
Cell Transformation, Neoplastic / genetics
Cell Transformation, Neoplastic / pathology
Chromosome Aberrations / chemically induced*
Chromosome Deletion*
Chromosomes, Human, Pair 5 / genetics*
Female
Humans
Janus Kinase 2 / genetics*
Lenalidomide / adverse effects*
Leukemia, Myeloid, Acute / etiology
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology*
Mutation*
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / genetics
Myelodysplastic Syndromes / pathology
Prognosis

Substances

Biomarkers, Tumor
JAK2 protein, human
Janus Kinase 2
Lenalidomide